ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 21, 2020 | $60,000 | Replaced |
| 4th Quarter - Amendment | Jan 22, 2020 | $60,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Animals ANI
Genetically engineered (GE) animals
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW K. COLE New | Intern for Senator Don Nickels (R-OK) |
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Fuel/Gas/Oil FUE
Biofuels, renewable chemicals/bio-based products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW K. COLE | — |
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Medicare/Medicaid MMM
Issues related to reimbursement under Medicare Part B generally Issues related to Medicare Part D, generally HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Value-based contracting and communications
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW K. COLE New | Intern for Senator Don Nickels (R-OK) |
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
| LYDIA STRUNK New | Deputy Floor Director Speaker Ryan (2015-17); Deputy Floor Director Speaker Boehner (2013-15); House Rules Committee 2011-13; House Republican Cloakroom Floor Assistant 2008-2011 (Minority Leader Boehner/Speaker Boehner) |
Taxation/Internal Revenue Code TAX
Vaccines and infectious diseases; antimicrobials
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW K. COLE | — |
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Health Issues HCR
Issued relating to the 340B Drug Pricing Program Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program Issues related to biosimilars, generally; access to samples for testing; coding; naming; interchangeability and pharmacy substitution; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the importation of prescription medicines, generally Issues related to drug patents and patent reporting requirements
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW K. COLE New | Intern for Senator Don Nickels (R-OK) |
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Budget/Appropriations BUD
Funding for antimicrobial resistance programs Funding for renewable chemicals/bio-based products Funding for biodefense and emergency preparedness research, development and procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW K. COLE | — |
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.